IBS Bloating: The 5 Mechanisms and What Actually Helps

If you have IBS, bloating is probably one of your most disruptive symptoms. It changes how your clothes fit. It changes whether you feel comfortable in social situations. It changes your relationship with food, with the evening, and sometimes with your own body. And the standard advice you have likely been given (cut out gluten, try a probiotic, take a peppermint capsule, do a low-FODMAP diet, drink less carbonation, eat slower) often delivers underwhelming results because the advice assumes a single cause. There are five separate mechanisms that produce IBS bloating. Each has a different fingerprint, a different timing pattern, a different physical examination finding, and a different evidence-based intervention. This page walks all five, then maps each one to what actually helps.

The first and most clinically useful distinction in this entire topic is the difference between bloating and distension. The two words are used interchangeably in everyday speech, but they describe two different things, and confusing them is the reason so many patients feel dismissed by their care providers and so many interventions are mismatched to the underlying problem.

Bloating is a subjective sensation. It is the felt experience of fullness, pressure, tightness, or swelling in the abdomen. It is what the patient reports. It can be present whether or not anything has changed about the physical size of the abdomen. It is processed in the brain, modulated by visceral nerve signalling, and influenced by attention, mood, and prior experience. Two patients with identical gut contents can have completely different bloating sensations depending on the sensitivity of their nervous system at that moment.

Distension is an objectively measurable increase in abdominal girth. It is what a tape measure or an ultrasound or a CT scan would show. It is a physical change in volume or in the shape of the abdominal wall. It is what an examiner can see and palpate. It can occur with or without bloating, and bloating can occur with or without it.

The four possible combinations

Once you separate sensation from volume, four combinations become visible, and each has a different clinical meaning:

• Bloating with distension. The patient feels swollen and the abdomen is measurably larger. This is the "classic" bloating presentation. Mechanisms typically include gas accumulation from fermentation, slow transit allowing build-up, abdominal-phrenic dyssynergia pushing the wall outward, or in some cases ascites or mass that needs a medical workup.
• Bloating without distension. The patient feels swollen but the abdomen is not measurably larger. This is the visceral-hypersensitivity-dominant pattern. The volume has not changed; the nervous system is interpreting normal contents as painful pressure. This is often the most dismissed and the most under-treated subgroup because there is nothing for an examiner to point at.
• Distension without bloating. The abdomen is measurably larger but the patient does not feel swollen. This is uncommon but occurs in some constipation-predominant patterns where the patient has adapted to the chronic distension and no longer registers it as a sensation. It is also seen in some chronic intestinal pseudo-obstruction patients.
• Neither bloating nor distension. The asymptomatic baseline most patients aspire to.

Why the distinction matters for treatment

If a patient has bloating without distension, the volume of gut contents was not the problem. Gas-reduction interventions (simethicone, low-FODMAP, charcoal, probiotics targeting fermentation) will not fix the experience because they are addressing a volume that did not need to change. The intervention has to act on the central nervous system processing of visceral signals, which is what brain-gut therapies are designed to do.

If a patient has bloating with substantial measurable distension, gas-reduction and motility interventions can directly help, because the volume component is real and modifiable. Layering in central interventions still adds value (because the sensation amplification is also part of the picture), but the peripheral interventions are now indicated rather than misdirected.

The bloating-distension distinction is also one of the cleanest tools for self-classification. A simple tape measure at the largest point of your abdomen, taken in the morning before eating and again at the end of the day at peak bloating, gives you a measurement. If the difference is less than 2 to 3 cm, you are likely bloating-dominant rather than distension-dominant, and central interventions deserve more attention in your plan. If the difference is 5 to 8 cm or more, distension is a meaningful component and peripheral mechanisms deserve more weight.

With this distinction in hand, the rest of the page becomes easier to navigate. The five mechanisms below each map to one of those four combinations, and each carries its own evidence-based intervention. For more on the central-nervous-system layer specifically, see the page on the gut-nerve sensitivity layer, which goes deeper on mechanism one.

Visceral hypersensitivity is the single most under-recognised driver of IBS bloating. It is also the mechanism behind the most dismissed presentation in clinic: the patient who feels persistently and severely bloated but whose abdomen looks unchanged on examination, whose imaging is normal, whose lab work is normal, and who has been told some version of "everything looks fine" while still living with daily symptoms that compromise quality of life. Everything is not fine. The mechanism is real, well-documented, and treatable. It is just not visible from the outside.

What visceral hypersensitivity actually is

Your gut sends an enormous amount of signalling to your brain at all times. Stretch receptors in the bowel wall, chemoreceptors that sense pH and luminal contents, and a dense network of enteric neurons constantly relay information about volume, motility, contents, and tissue state. In a healthy person, the vast majority of this signalling is filtered out before it reaches conscious awareness. You do not feel every contraction. You do not feel every gas pocket move. You do not feel every milligram of fermentation product hitting a chemoreceptor. The signals are processed, integrated, and most of them never reach the level of perception.

Visceral hypersensitivity is the state in which that filter fails. Normal volumes of gas, normal contractions, and normal stretching of the bowel wall are amplified into conscious perception as pain, pressure, fullness, or bloating. The volume of contents has not changed. The sensitivity of the system processing those contents has changed. The patient experiences as severe bloating what would be entirely sub-perceptual in a person with normal visceral signal processing.

Where the amplification happens

The amplification is multi-level. There is a peripheral component (the gut nerves themselves can become more reactive after inflammation, infection, or chronic stress exposure). There is a spinal component (signals get amplified as they pass through the dorsal horn). And there is a central component (the brain regions that process visceral signals, particularly the anterior cingulate cortex and the insula, show altered activation in IBS patients on functional imaging). The relative contribution of each layer varies between patients, which is one reason different interventions work differently for different people.

The implication is that reducing gas alone does not fix the bloating experience for visceral-hypersensitivity-dominant patients. You can take simethicone, you can do low-FODMAP, you can take activated charcoal, and the underlying perception-amplification system continues to do its work on whatever volume of contents remains. The intervention has to act on the signalling and processing pathway, not just on the substrate.

Clinical fingerprint of visceral-hypersensitivity bloating

The pattern that points to this mechanism includes severe bloating sensation with little or no measurable distension, bloating that persists between meals and through periods of low food intake, bloating that does not predictably respond to gas-reduction interventions, bloating that is worse during stress and better during deep relaxation, and bloating that often coexists with other visceral pain (cramping, generalised abdominal pain, urgency without proportionate stool volume). Patients with this pattern often describe feeling "swollen from the inside out" or "like there is pressure that has nowhere to go," even when external observers cannot see any change.

The intervention layer that targets this mechanism is brain-gut therapy: gut-directed hypnotherapy, cognitive behavioural therapy adapted for IBS, and certain neuromodulators (low-dose tricyclic antidepressants used for their visceral-pain-dampening effect rather than for depression). Each acts on the central component of the perception-amplification system rather than on peripheral gas or volume.

Abdominal-phrenic dyssynergia (APD) is one of the more recently characterised drivers of visible bloating, and it is one of the most rewarding to identify because it is genuinely treatable with a targeted technique that most patients have never been offered. The work characterising APD has come largely from Barba and colleagues in Spain, using simultaneous electromyography and abdominal imaging to capture what the abdominal wall and diaphragm are actually doing during episodes of patient-reported bloating.

The normal motor pattern

In normal physiology, when intra-abdominal volume increases (after a meal, during gas accumulation, during the day's natural transit), the body accommodates the volume in a coordinated way. The diaphragm relaxes upward, increasing the vertical space the abdominal contents have to occupy. The abdominal wall muscles maintain tone, keeping the front of the abdomen relatively flat. The result is that mild to moderate volume changes are absorbed largely by movement of the diaphragm rather than by visible distension of the abdominal wall.

The APD pattern

In abdominal-phrenic dyssynergia, the opposite happens. When intra-abdominal volume increases, the diaphragm contracts and descends (rather than relaxing upward), and the abdominal wall muscles relax outward (rather than maintaining tone). The contents now have nowhere to go but forward. The result is the dramatic visible distension that many bloating-dominant IBS patients describe, often appearing rapidly after meals and resolving overnight when the patient is supine and the postural component is removed.

The pattern is a learned, abnormal motor response. It is not a structural problem. The muscles are healthy, the nerves are intact, the wiring works. What has gone wrong is the coordination, and coordination problems are addressable through retraining.

Biofeedback retraining

The intervention that targets APD specifically is biofeedback. The patient is given real-time visual or electromyographic feedback on their diaphragm and abdominal wall activity. Through guided practice across typically 6 to 12 sessions, they relearn the normal coordinated pattern (diaphragm relaxes upward, abdominal wall maintains tone) in response to volume challenges. Studies of biofeedback for APD report meaningful reductions in objectively measured distension and in subjective bloating in responders, with effects that often persist after the active treatment ends.

The clinical implication is that patients with the visible-distension pattern, especially the morning-flat to evening-distended cycle that fits APD, should at least be aware that biofeedback exists as an option. It is not yet widely available outside specialist motility centres, but the procedure is not technically demanding and access is gradually expanding.

Motility refers to the coordinated muscle contractions that move contents through the gut. Transit is the resulting time it takes for material to travel from one part of the GI tract to another. Both contribute to bloating in distinct ways, and abnormalities in either can produce or worsen the symptom.

Slow colonic transit increases fermentation time

The longer contents sit in the colon, the longer the resident bacterial population has to ferment any unabsorbed carbohydrates that arrive there. Fermentation produces hydrogen, methane, and carbon dioxide as byproducts. The slower the transit, the more cumulative gas production. The more cumulative gas production, the more luminal volume. The more luminal volume, the more wall distension and (in a sensitised gut) the more bloating sensation. This is why constipation-predominant IBS (IBS-C) so commonly has more prominent bloating than diarrhea-predominant IBS (IBS-D), even though both subtypes can have severe bloating.

The clinical implication is that any intervention that improves colonic transit (adequate soluble fibre, hydration, regular meal timing, prokinetic medications when appropriate, treatment of underlying constipation) can secondarily reduce bloating by reducing the time available for fermentation. Patients with the IBS-C plus bloating combination often see meaningful bloating reduction when the constipation is addressed properly, even if no other bloating-targeted intervention is added.

Disordered MMC and small bowel bacterial overgrowth

Between meals, the small bowel performs a housekeeping function called the migrating motor complex (MMC). These are coordinated waves of contraction that sweep residual contents from the stomach through the small intestine into the colon, partly to keep bacterial populations in the small bowel low. When the MMC is disordered (which can happen after gastroenteritis, with diabetes, with certain neurological conditions, or as part of chronic IBS), bacterial populations can establish themselves in the small bowel where they are not normally supposed to thrive. The result is small intestinal bacterial overgrowth, or SIBO.

SIBO produces a characteristic bloating pattern: rapid post-meal onset (within 30 to 90 minutes), often with significant visible distension, often with audible gurgling and changes in stool pattern. SIBO is diagnosed with a hydrogen and methane breath test and treated with targeted antibiotics, sometimes followed by prokinetic therapy to support MMC function and reduce recurrence. A meaningful subset of bloating-dominant IBS patients have SIBO as a co-driver, and treating it can produce significant symptom improvement that no amount of dietary or central intervention would have achieved. For more on telling SIBO apart from IBS proper and from inflammatory bowel disease, see the page on differential diagnosis when SIBO is suspected.

The paradoxical pro-motility result

Sometimes pro-motility interventions reduce bloating in counter-intuitive ways. A patient with slow transit and bacterial overgrowth in the colon may find that increasing motility (with appropriate prokinetics or dietary changes) actually reduces their bloating, because the colonic contents are now spending less time available for fermentation and the bacterial load is being cleared more efficiently. Patients sometimes resist this on the assumption that "more motility means more diarrhea, which is not what I want." The actual outcome in slow-transit-plus-bloating patients is often the opposite: more regular bowel movements, less retained content, and substantially reduced bloating.

The gut microbiome is one of the more popular topics in current health writing, often with claims that outpace the actual evidence. The disciplined position for IBS bloating specifically is that the microbiome contributes through one well-characterised mechanism (fermentation of certain dietary substrates into gas) and through several less-established mechanisms (immune signalling, microbial metabolite production, indirect effects on motility and barrier function).

FODMAPs and bacterial gas production

FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) are a group of short-chain carbohydrates that the small intestine often does not fully absorb. The unabsorbed portion arrives in the colon, where it serves as substrate for bacterial fermentation. The byproducts are hydrogen, methane, carbon dioxide, and short-chain fatty acids. The gas produced increases luminal volume. In a sensitised gut, the increased volume produces increased bloating.

The classic high-FODMAP foods include large servings of garlic and onion, wheat and rye products, certain fruits (apples, pears, mangoes, watermelon, stone fruits), most beans and lentils, lactose-containing dairy, and certain artificial sweeteners (sorbitol, mannitol, xylitol). The low-FODMAP diet developed at Monash University systematically restricts these substrates for an elimination phase, then reintroduces them individually to identify each patient's specific triggers.

Why low-FODMAP works for some and not others

The published trial data put response rates at roughly 50 to 70% of IBS patients. The reason it does not approach 100% is straightforward: not every IBS patient's bloating is driven primarily by fermentation. If your dominant mechanism is visceral hypersensitivity (mechanism one) or abdominal-phrenic dyssynergia (mechanism two), reducing fermentable substrate will not address the actual driver. You may get a partial response from the lower overall gas load, but the central or motor component continues to do its work.

Conversely, patients whose bloating is dominantly fermentation-driven often see dramatic and rapid improvement on low-FODMAP, sometimes within the first one to two weeks. The pattern that predicts a strong response includes bloating that worsens predictably after high-FODMAP meals, audible gurgling and visible distension within an hour or two of eating, gas production that the patient or their household can clearly notice, and a meaningful reduction in symptoms during periods of low food intake.

For a deeper comparison of the dietary and brain-gut approaches and how they overlap, see the page on FODMAP for fermentation-driven bloating. The two approaches are not mutually exclusive and are sometimes layered.

SIBO as a microbiome variant

As covered in the motility section, SIBO is the establishment of bacterial populations in the small bowel where they are not normally supposed to thrive. From the microbiome perspective, SIBO is an example of microbial dysbiosis that produces prominent bloating through the same fermentation mechanism, but in the wrong location (small bowel rather than colon). The clinical implication is that a subset of IBS-bloating patients who have not responded well to low-FODMAP may be carrying SIBO that has not yet been identified, and breath testing is worth considering when the pattern fits.

The probiotic question, framed honestly

Probiotics for IBS bloating have a mixed and strain-specific evidence picture. Some trials of specific strains (Bifidobacterium infantis 35624 is the most commonly cited) report modest bloating reduction. Other trials of other strains show no benefit. The evidence is not strong enough to make blanket recommendations, but the disciplined position is that a single trial of one product with published evidence, taken consistently for at least four weeks with tracking of bloating severity, is a reasonable low-cost experiment. If there is no detectable benefit at four weeks, the product is not working for that patient.

The fifth mechanism is mechanical rather than gut-nerve in origin, and it is the one that gets the least attention in IBS-bloating literature precisely because it falls outside the gut itself. It still matters, particularly for patients whose subjective bloating sensation does not fit cleanly into mechanisms one through four.

Visceral adipose tissue reduces accommodation space

Visceral fat is the adipose tissue that surrounds the abdominal organs, distinct from subcutaneous fat that sits between the skin and the muscle layer. Increased visceral fat physically reduces the space available inside the abdominal cavity for normal gut accommodation. The same volume of intraluminal contents now produces more pressure against the abdominal wall, more apparent distension, and (in a sensitised gut) more bloating sensation. Two patients with identical gut contents and identical fermentation profiles can have different bloating experiences if one has substantially more visceral adiposity than the other.

The clinical implication is not that bloating is "caused by being overweight," which is both stigmatising and inaccurate. The implication is that visceral fat is one mechanical contributor among several, and that addressing it (where appropriate and where the patient is interested) can be one component of a layered plan rather than a standalone intervention. Improvements in visceral fat are best achieved through general fitness and dietary patterns rather than through targeted abdominal exercise, which does not preferentially reduce visceral adipose tissue.

Postural collapse exaggerates apparent bloating

Posture is the second component of this mechanism, and it is often more impactful than patients expect. Through a day of sitting, the postural muscles fatigue. The pelvis tilts anteriorly. The lumbar curve flattens. The abdominal wall protrudes more visibly. Patients who track their abdomen size through the day often notice that their evening "bloating" is in part a postural effect rather than entirely a volume effect.

The targeted interventions are general core conditioning, hip flexor mobility (tight hip flexors anteriorly tilt the pelvis and exaggerate apparent bloating), thoracic mobility (collapsed thoracic posture compresses the abdomen vertically and pushes contents forward), and breathing pattern work (chest-dominant breathing fails to engage the diaphragm properly and contributes to APD-pattern presentations). None of these is a quick fix, but they collectively reduce the postural component of apparent bloating.

Why this mechanism is treated separately

The visceral-fat-and-posture mechanism is mechanical rather than gut-nerve. Brain-gut interventions, dietary FODMAP restriction, biofeedback for APD, and prokinetics for transit issues will not change visceral adipose tissue or postural collapse. The intervention category is general fitness, body composition, and posture work, which sits outside the gut-specific toolkit but contributes meaningfully to the overall picture.

The reason "try X for bloating" advice fails so often is that X almost always targets one of the five mechanisms, and the patient's bloating is driven by a different one. The clean approach is to identify which mechanism best fits the patient's pattern (using the timing, response to meals, response to bowel movements, and presence or absence of measurable distension as clues) and then match the intervention to the mechanism. The five-mechanism framework is most useful as a self-classification tool that lets the patient stop trying interventions that were never going to work for their particular physiology.

Visceral hypersensitivity (mechanism 1)

The interventions that act on this mechanism are central rather than peripheral. Gut-directed hypnotherapy on the Manchester Protocol has the strongest evidence base for IBS specifically, with documented effects on central pain processing and durable response in long-term follow-up. Cognitive behavioural therapy adapted for IBS has comparable evidence and a similar central mechanism. Low-dose tricyclic antidepressants (used at sub-antidepressant doses for their visceral pain dampening effect) are sometimes used by gastroenterologists for the same target. SSRIs have weaker evidence for visceral pain specifically but can be useful where there is significant comorbid anxiety or depression. Mindfulness-based interventions have growing evidence as adjuncts. The peripheral interventions (gas reducers, low-FODMAP, simethicone) are not contraindicated but should be understood as treating a co-driver rather than the primary mechanism.

Abdominal-phrenic dyssynergia (mechanism 2)

Biofeedback that retrains the diaphragm-abdominal coordination is the targeted intervention. Sessions are typically 6 to 12, delivered at specialist motility centres. The intervention has a low side-effect profile and meaningful published evidence in characterised APD patients. Diaphragmatic breathing practice between sessions consolidates the retrained pattern and is often continued indefinitely. Postural work (covered under mechanism 5) often layers usefully because postural collapse can drive APD-pattern responses.

Motility and transit (mechanism 3)

The interventions are subtype-specific. For slow transit and constipation-predominant patterns: adequate soluble fibre (psyllium is the most commonly used), hydration, regular meal timing, treatment of underlying constipation with osmotic laxatives where appropriate, and pro-motility medications under physician supervision when needed. For SIBO confirmed by breath testing: targeted antibiotics (commonly rifaximin, sometimes with adjunct agents depending on the gas profile) followed by prokinetic therapy to reduce recurrence. For functional motility patterns more generally: gut-directed hypnotherapy has documented effects on autonomic regulation that secondarily modulate motility, which is one reason GDH appears in multiple mechanism categories.

Microbiome and fermentation (mechanism 4)

The structured low-FODMAP protocol (elimination, reintroduction, personalisation phases) under dietitian guidance is the highest-evidence dietary intervention. Targeted antibiotics for confirmed SIBO are the medical intervention when overgrowth is the driver. Specific probiotic strains with published trial evidence (Bifidobacterium infantis 35624 is the most commonly cited) can be tried as a low-cost adjunct with a four-week assessment window. Avoiding indefinite strict low-FODMAP eating matters; the protocol is designed for personalisation, not for permanent severe restriction, which carries documented downsides for the microbiome and for quality of life.

Visceral fat and posture (mechanism 5)

General aerobic fitness in the moderate-intensity range, resistance training in modest volumes, dietary patterns that support healthy body composition, and targeted postural work (hip flexor mobility, thoracic extension, core conditioning) collectively address the mechanical component. None of this is rapid, none of it is gut-specific, and none of it should be framed as bloating-cure messaging that pressures patients about weight. It is one mechanism among five, and patients who are interested can address it on their timeline.

Gut-directed hypnotherapy (GDH) on the Manchester Protocol earns a place in the bloating toolkit primarily through mechanism one (visceral hypersensitivity), with secondary effects that touch mechanism two and mechanism three. It is not a universal bloating cure, and it is not the right tool for every patient or every mechanism. The honest framing is that GDH is one of several mechanism-matched interventions, particularly well-suited to the bloating-without-distension subgroup that other interventions often fail to help.

Direct effect on visceral hypersensitivity

The Manchester Protocol uses a structured 8 to 12 session sequence of induction, deepening, and gut-targeted suggestion to retrain visceral signal processing. Functional imaging studies in patients who respond to GDH show altered activation in central pain regions including the anterior cingulate cortex and the insula, consistent with central rather than peripheral mechanism of action. For the patient whose bloating is dominantly produced by amplified perception rather than by changed volume, this is precisely the right intervention layer.

Indirect effect on abdominal-phrenic dyssynergia

The trained relaxation response that builds across GDH sessions includes sustained diaphragmatic relaxation and reduced abdominal wall guarding. This is not the targeted biofeedback intervention specific to APD, but in patients with mild APD-pattern responses driven partly by chronic abdominal-wall tension, the indirect effect of GDH-trained relaxation can produce meaningful improvement. Patients with severe characterised APD still benefit most from formal biofeedback; GDH is an adjunct, not a replacement.

Indirect effect on motility

Autonomic regulation shifts toward parasympathetic dominance during and following GDH sessions. Parasympathetic dominance supports normal motility patterns. In patients whose motility disturbance has a stress-driven component, GDH can produce secondary improvements in transit and reduce the bloating that follows from slow transit and increased fermentation time. Again, the effect is indirect and is one part of a layered approach.

The bloating-without-distension subgroup

The patients who consistently get the most from GDH for bloating are those whose pattern fits the bloating-without-distension profile: severe bloating sensation, little or no measurable distension, persistent symptoms that do not predictably respond to gas-reduction interventions, often coexisting with other visceral pain or anxiety overlap. For this subgroup, the standard dietary and motility-targeted interventions tend to underperform precisely because the volume was never the problem. GDH addresses the actual driver. For more on what GDH involves session-by-session and what response looks like, see the page on GDH for visceral-hypersensitivity bloating.

Evidence summary, framed honestly

Three findings from the GDH evidence base are worth holding in mind when considering it for bloating specifically. Miller 2015 (PMID 25736234) reported 76% response in 1,000 consecutive refractory IBS patients on the Manchester Protocol; this is benchmark real-world clinic data, not RCT evidence, and the patients had already failed first-line medical management before referral. Peters 2016 (PMID 27397586) reported equivalence to the low-FODMAP diet in a randomised controlled trial, with both interventions producing significant and clinically meaningful improvement and no statistically significant difference between arms at 6-month follow-up. Hasan 2019 (PMID 30702396) reported that 76% of GDH-treated patients maintained their initial improvement at 5+ year follow-up versus 65% in a medical-management comparison group, supporting unusual durability for an IBS intervention.

Honest framing: GDH is one tool, not the whole toolkit

For the patient whose bloating is fermentation-driven (mechanism four), low-FODMAP under dietitian guidance is the higher-yield first step and GDH is an adjunct. For the patient with visible APD-pattern distension (mechanism two), formal biofeedback is the higher-yield first step and GDH is an adjunct. For the patient with constipation-predominant slow transit (mechanism three), addressing the constipation is the higher-yield first step. For the patient whose dominant driver is mechanism one (visceral hypersensitivity), GDH is genuinely first-line and the dietary or motility-targeted interventions are the adjuncts.

What this practice offers

The clinic offers gut-directed hypnotherapy following the Manchester Protocol, delivered both virtually (across Canada) and in-person in Calgary, Alberta. The per-session fee is $220 CAD. Standard initial commitment is 3 sessions ($660 CAD total). Continuation beyond the initial 3 sessions is optional. There are no admin fees, and the price is the same virtual or in-person.

Conditions worked with include IBS (all subtypes, including IBS-D, IBS-C, IBS-M, IBS-U), SIBO as adjunct to medical treatment, functional dyspepsia, post-infectious IBS, visceral hypersensitivity, and IBS with anxiety overlap. Sessions are paid at time of service, and a detailed receipt is provided with the practitioner's ARCH registration number.

Hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking.